Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | ULK1 | O75385 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCND2 | P30279 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483272 | 0.93 | WEE1 (0.52) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4491903 | 0.91 | PTK2 (0.45) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4487639 | 0.91 | EGFR (0.50) | EGFRALKPTK2BRD4ULK1 | |
| SCHEMBL4487608 | 0.90 | EGFR (0.43) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4483955 | 0.78 | ALK (0.55) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4483961 | 0.78 | ALK (0.55) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4480403 | 0.76 | PTK2 (0.47) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4480396 | 0.76 | PTK2 (0.47) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4483052 | 0.76 | EGFR (0.46) | EGFRWEE1ALKPTK2BRD4 | |
| SCHEMBL4483048 | 0.76 | EGFR (0.46) | EGFRWEE1ALKPTK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989198-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-09 | — | — | EP | claimed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | claimed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | claimed |
| EP-1989198-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | EGFR 280/4885WEE1 483/4885ALK 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.